Whereas three high-risk patients with relapsed tumors with neither MYCN amplification nor ARID1B mutations were rescued with salvage treatment after relapse, two relapsed patients with ARID1B mutations died of tumor progression. The gene discussed is MYCN; the disease is neoplasm.